🚀 VC round data is live in beta, check it out!
Lytix Biopharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Lytix Biopharma and similar public comparables like Q32 Bio, OKYO Pharma, Seres Therapeutics, NRX Pharmaceuticals and more.
Lytix Biopharma Overview
About Lytix Biopharma
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. Its products, LTX-401 and LTX-315, are in the pipeline. The company operates in Norway and the USA, majority of revenue is from the USA.
Founded
2003
HQ
Employees
11
Website
Sectors
Financials (LTM)
EV
$78M
Lytix Biopharma Financials
Lytix Biopharma reported last 12-month revenue of $638K and negative EBITDA of ($6M).
In the same LTM period, Lytix Biopharma generated $638K in gross profit, ($6M) in EBITDA losses, and had net loss of ($6M).
Revenue (LTM)
Lytix Biopharma P&L
In the most recent fiscal year, Lytix Biopharma reported revenue of — and EBITDA of ($6M).
Lytix Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $638K | XXX | — | XXX | XXX | XXX |
| Gross Profit | $638K | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($6M) | XXX | ($6M) | XXX | XXX | XXX |
| EBITDA Margin | (942%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (877%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($6M) | XXX | ($6M) | XXX | XXX | XXX |
| Net Margin | (908%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Lytix Biopharma Stock Performance
Lytix Biopharma has current market cap of $86M, and enterprise value of $78M.
Market Cap Evolution
Lytix Biopharma's stock price is $1.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $78M | $86M | 1.7% | XXX | XXX | XXX | $-0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLytix Biopharma Valuation Multiples
Lytix Biopharma trades at 122.4x EV/Revenue multiple, and (13.0x) EV/EBITDA.
EV / Revenue (LTM)
Lytix Biopharma Financial Valuation Multiples
As of April 18, 2026, Lytix Biopharma has market cap of $86M and EV of $78M.
Equity research analysts estimate Lytix Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lytix Biopharma has a P/E ratio of (14.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $86M | XXX | $86M | XXX | XXX | XXX |
| EV (current) | $78M | XXX | $78M | XXX | XXX | XXX |
| EV/Revenue | 122.4x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (13.0x) | XXX | (12.4x) | XXX | XXX | XXX |
| EV/EBIT | (13.9x) | XXX | (12.8x) | XXX | XXX | XXX |
| EV/Gross Profit | 122.4x | XXX | — | XXX | XXX | XXX |
| P/E | (14.8x) | XXX | (13.3x) | XXX | XXX | XXX |
| EV/FCF | (13.3x) | XXX | (12.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lytix Biopharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Lytix Biopharma Margins & Growth Rates
Lytix Biopharma's revenue in the last 12 month grew by 138%.
Lytix Biopharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.6M for the same period.
Lytix Biopharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 138% | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | (942%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | (43%) | XXX | (31%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 371% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Lytix Biopharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Lytix Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Q32 Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| OKYO Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Seres Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| NRX Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| aTyr Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lytix Biopharma M&A Activity
Lytix Biopharma acquired XXX companies to date.
Last acquisition by Lytix Biopharma was on XXXXXXXX, XXXXX. Lytix Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Lytix Biopharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLytix Biopharma Investment Activity
Lytix Biopharma invested in XXX companies to date.
Lytix Biopharma made its latest investment on XXXXXXXX, XXXXX. Lytix Biopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Lytix Biopharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lytix Biopharma
| When was Lytix Biopharma founded? | Lytix Biopharma was founded in 2003. |
| Where is Lytix Biopharma headquartered? | Lytix Biopharma is headquartered in Norway. |
| How many employees does Lytix Biopharma have? | As of today, Lytix Biopharma has over 11 employees. |
| Is Lytix Biopharma publicly listed? | Yes, Lytix Biopharma is a public company listed on Oslo Børs. |
| What is the stock symbol of Lytix Biopharma? | Lytix Biopharma trades under LYTIX ticker. |
| When did Lytix Biopharma go public? | Lytix Biopharma went public in 2021. |
| Who are competitors of Lytix Biopharma? | Lytix Biopharma main competitors are Q32 Bio, OKYO Pharma, Seres Therapeutics, NRX Pharmaceuticals. |
| What is the current market cap of Lytix Biopharma? | Lytix Biopharma's current market cap is $86M. |
| What is the current revenue of Lytix Biopharma? | Lytix Biopharma's last 12 months revenue is $638K. |
| What is the current revenue growth of Lytix Biopharma? | Lytix Biopharma revenue growth (NTM/LTM) is 138%. |
| What is the current EV/Revenue multiple of Lytix Biopharma? | Current revenue multiple of Lytix Biopharma is 122.4x. |
| Is Lytix Biopharma profitable? | No, Lytix Biopharma is not profitable. |
| What is the current EBITDA of Lytix Biopharma? | Lytix Biopharma has negative EBITDA and is not profitable. |
| What is Lytix Biopharma's EBITDA margin? | Lytix Biopharma's last 12 months EBITDA margin is (942%). |
| What is the current EV/EBITDA multiple of Lytix Biopharma? | Current EBITDA multiple of Lytix Biopharma is (13.0x). |
| What is the current FCF of Lytix Biopharma? | Lytix Biopharma's last 12 months FCF is ($6M). |
| What is Lytix Biopharma's FCF margin? | Lytix Biopharma's last 12 months FCF margin is (919%). |
| What is the current EV/FCF multiple of Lytix Biopharma? | Current FCF multiple of Lytix Biopharma is (13.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.